CA-BEHAVIOSEC
21.4.2021 09:02:13 CEST | Business Wire | Press release
BehavioSec , the industry pioneer and technology leader for behavioral biometrics and continuous authentication, today announced new findings that organizations and consumers can feel more comfortable with wider use of behavioral biometrics to safeguard their online digital experiences and identities.
Following a year of digital transformation on a societal level, the demand for better online user experience and a stronger level of digital identity protection has become essential. With a year when the world has seen a combination of personal data theft with new rulings and proposed legislation, like the EU Schrems II in July 2020 and the US National Biometrics Information Privacy Act in August [US Senators Merkley, D-OR and Sanders, I-VT], the need for expert guidance has never been higher. BehavioSec shares this research and a company milestone to highlight how behavioral biometrics can be adopted transparently with clear benefits, and in compliant fashion with comprehensive data protection laws. These include measures like the European General Data Protection Regulation (GDPR), the European Commission’s PSD2/SCA and its Open Banking mandate, the US California Consumer Privacy Act (CCPA) and similar, anticipated requirements of regulations proposed in other regions.
To validate the safe use of behavioral biometrics at a time when headlines are full of allegations about technologies like facial recognition and “deep fake” simulations being abused, BehavioSec sponsored the report, “2021 Global Data Privacy Regulation of Physical & Behavioral Biometrics” by respected industry research firm Goode Intelligence . In the report, Chief Analyst Alan Goode dives into the relevance of current and proposed global privacy and data protection legislation on the successful and compliant adoption of biometrics technology for authentication and identity verification, and addresses the key questions organizations and consumers are asking:
- Where do the next wave of behavioral-based technologies fit?
- How do they impact our delicate balance between security, privacy, and regulation?
- Are they covered under existing and proposed regulation?
- Will behavior-based technology make matters worse - or much better?
Leveraging global bank customer input, extensive research, and legal opinion from attorneys at international law firm Osborne Clarke , the paper outlines how enterprises can confidently use behavioral biometrics while complying with some of the strictest privacy and data protection laws in the world, including GDPR, industry payment regulations like PSD2 SCA, and 3D Secure 2.0 technology.
“As we move more of our personal and business tasks online, it is becoming increasingly important to secure digital channels,” says Goode. “Mobile security is more important than ever before and behavioral biometric technology has proven itself as a vital tool in enabling secure access to digital services, preventing fraudsters from gaining access, all while remaining compliant to GDPR, among others.”
A US-based webcast, “Biometrics & Digital Identity Verification – 2021 Data Protection & Privacy Regulation Insights” will be broadcast on May 25, 2021 featuring a presentation by Alan Goode on his report’s findings and offer further insight on data privacy, digital transformation and fighting fraud and cybercrime using biometrics. Viewers can register to watch the webinar hosted by BehavioSec and IDG including a discussion between CSO’s Bob Bragdon, Alan Goode and an expert panel including Dr. Shane Shook, Financial Crimes Investigator and Venture Consultant at ForgePoint Capital, Jordan Blake, BehavioSec Vice President of Products, and Jake Bernstein J.D., attorney at Focal PLLC and former Washington State Assistant Attorney General.
“It is crucial to proactively stir these debates now on how new technologies define identity and authentication, before assumptions and lack of transparency – even if unintended – irrevocably shake public and policymakers’ trust,” added Jake Bernstein, who specialized in prosecuting consumer protection cases during his time in the U.S. Washington State Attorney General’s office. “The boundary between improving digital trust and triggering privacy and identity crises does not have to be a slippery slope where biometric-based systems are concerned. Yet, perceived missteps and alleged abuse of facial-recognition and other innovations to-date show us what stakeholders, including businesses, have to avoid.”
Additionally, on May 26th at 3:00pm BST/4:00pm CEST, Goode will host a second webcast, “2021 Global Regulation of Physical & Behavioral Biometrics for Digital Identity Verification” , to present his research on the impacts of privacy and data protection regulation on the implementation of biometrics by businesses, particularly across the European Union. As the Founder, CEO, and Chief Analyst of Goode Intelligence, Goode is a respected expert in information security and biometrics and will offer insights on how businesses may be able to consider their specific use cases and possible exceptions for explicit consent according to GDPR regulation. Goode will be joined by BehavioSec and international law firm Osborne Clarke, who BehavioSec commissioned to advise on the regulatory impact to customer deployments of the BehavioSec behavioral biometrics platform , specifically within the German banking sector.
“There’s no question that technology vendors need to continue to work collaboratively with government and business to ensure better protection and experience for consumers and employees while staying fully compliant,” said BehavioSec CEO Neil Costigan. “As the pioneer in this space, we’re offering this research to the market to open the dialogue, and we’re also demonstrating and modeling compliance as a company. Beyond our ongoing support of GDPR and security best practices, we are happy to share our recent SOC2 Type1 certification and our active program for Type 2 and ISO 27001.”
To access this research, the public can download Alan Goode’s report and join the public webcasts with CSO [IDG] in the US on May 25th and with Goode Intelligence in Europe on May 26th .
About BehavioSec
BehavioSec is the industry pioneer and technology leader for behavioral biometrics and continuous authentication, safeguarding millions of users and billions of transactions today.
Deployed across Global 2000 companies to dramatically reduce fraud, friction, threat, and theft, BehavioSec verifies and protects human digital identities by understanding how we uniquely type and swipe across our ever-changing devices. Whether used in the Cloud or on-premises, BehavioSec delivers the superior user experience, precision, and scale needed by organizations to keep customers engaged while catching evasive, real-time attacks other solutions miss.
Founded in the Nordics in 2008 out of groundbreaking research, industry-recognized BehavioSec partners with market leaders and organizations like DARPA, and has earned investment from top investment firms like ForgePoint Capital, Cisco, ABN AMRO, Conor Ventures, and Octopus Ventures. Headquartered in San Francisco, CA with offices worldwide, BehavioSec is ready to help you reduce risk, improve compliance, and digitally transform your distributed workforce and customer experience. www.behaviosec.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210421005101/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release
–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
